William D. Figg

37.8k citations

604 papers · 25.3k indexed · 2 hit papers · h-index 86

Impact in

Oncology top 0.05%
- Drug Transport and Resistance Mechanisms
- Cancer Treatment and Pharmacology
Cancer Research top 0.2%

Papers in

Oncology 295
- Cancer Treatment and Pharmacology 91
- Drug Transport and Resistance Mechanisms 53
Hematology 103
- Multiple Myeloma Research and Treatments 83

Co-authors: Alex Sparreboom Seth M. Steinberg Cindy H. Chau Charity D. Scripture William L. Dahut Cody J. Peer Tristan M. Sissung Douglas K. Price
Journals: Journal of Clinical Oncology (101 papers)Clinical Cancer Research (36 papers)Cancer Biology & Therapy (35 papers)Blood (17 papers)Cancer Chemotherapy and Pharmacology (15 papers)
Partner nations: United States United Kingdom Netherlands

In The Last Decade

William D. Figg

593 papers receiving 24.7k citations

Hit Papers

align trajectories log scale

Antibody–drug conjugates for cancer 2019 · 574 citations

Peers

Countries citing papers authored by William D. Figg

Since Specialization

Citations

This map shows the geographic impact of William D. Figg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William D. Figg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William D. Figg more than expected).

Fields of papers citing papers by William D. Figg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William D. Figg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William D. Figg. The network helps show where William D. Figg may publish in the future.

Co-authorship network

The 25 scholars most cited alongside William D. Figg, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with William D. Figg Line = papers co-authored together William D. Figg links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Relugolix in Clinical Practice: The Best Route for All? The Oncologist ·Lisa M. Cordes, Fatima Karzai, William D. Figg, Ravi A. Madan	2023	6
2	Antitumor Activity of NLG207 (Formerly CRLX101) in Combination with Enzalutamide in Preclinical Prostate Cancer Models Molecular Cancer Therapeutics ·Keith T. Schmidt, Cindy H. Chau, Jonathan D. Strope, Alwin D. R. Huitema, Tristan M. Sissung, Douglas K. Price, William D. Figg	2021	18
3	A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor Models Cancer Research ·Shaun D. Fontaine, Gary W. Ashley, Peter J. Houghton, Raushan T. Kurmasheva, Morgan E. Diolaiti, Alan Ashworth, Cody J. Peer, Sunita S Malaj, William D. Figg, Denis Beckford-Vera, Daniel V. Santi	2020	16
4	Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy Clinical Cancer Research ·Kristin C. Hicks, Karin M. Knudson, Karin L. Lee, Duane H. Hamilton, James W. Hodge, William D. Figg, Peter Ordentlich, Frank R. Jones, Shahrooz Rabizadeh, Patrick Soon‐Shiong, Jeffrey Schlom, Sofia R. Gameiro	2019	37
5	IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion Clinical Cancer Research ·Kevin C. Conlon, E. Lake Potter, Stefania Pittaluga, Chyi‐Chia Richard Lee, Miloš D. Miljković, Thomas A. Fleisher, Sigrid Dubois, Bonita R. Bryant, Michael Petrus, Liyanage P. Perera, Jennifer L. Hsu, William D. Figg, Cody J. Peer, Joanna H. Shih, Jason L. Yovandich, Stephen P. Creekmore, Mario Roederer, Thomas A. Waldmann	2019	95
6	Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma Clinical Cancer Research ·Christine Alewine, Yang Wen-Guang, Cody J. Peer, Zishuo I. Hu, Min-Jung Lee, Akira Yuno, P. SLADKÝ, Anish Thomas, Seth M. Steinberg, Jane B. Trepel, William D. Figg, Raffit Hassan, Ira Pastan	2019	40
7	A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma Clinical Cancer Research ·Ramya Ramaswami, Thomas S. Uldrick, Mark N. Polizzotto, Kathleen M. Wyvill, Priscila Gonçalves, Kathline H. Kim, Kathryn Lurain, Seth M. Steinberg, William D. Figg, Giovanna Tosato, Denise Whitby, Robert Yarchoan	2019	23
8	Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors Molecular Cancer Therapeutics ·Laetitia Marzi, Keli Agama, Junko Murai, Simone Difilippantonio, K H Chandrakanth, Cody J. Peer, William D. Figg, E. Niebuhr, Mohamed Elsayed, Mark Cushman, Yves Pommier	2018	32
9	Pomalidomide for Symptomatic Kaposi's Sarcoma in People With and Without HIV Infection: A Phase I/II Study Journal of Clinical Oncology ·Mark N. Polizzotto, Thomas S. Uldrick, Kathleen M. Wyvill, Karen Aleman, Cody J. Peer, Margaret Bevans, Irini Sereti, Frank Maldarelli, Denise Whitby, Vickie Marshall, Priscila Gonçalves, Vikram Khetani, William D. Figg, Seth M. Steinberg, Jerome B. Zeldis, Robert Yarchoan	2016	86
10	Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells Clinical Cancer Research ·Mahadev Rao, João Frederico Clemente Pinto Santos Gonçalves, Vivek Shukla, Young Ki Hong, Trevor Upham, R. Taylor Ripley, Julie A. Hong, Mary Zhang, Laura Estacio Cerquin, Patricia Fetsch, Markku Miettinen, Xinmin Li, Cody J. Peer, Tristan M. Sissung, William D. Figg, Assunta De Rienzo, Raphael Bueno, David S. Schrump	2015	25
11	A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study Clinical Cancer Research ·Anish Thomas, Arun Rajan, Éva Szabó, Yusuke Tomita, Corey A. Carter, Barbara Scepura, Ariel López-Chávez, Min-Jung Lee, Christophe E. Redon, Gayatri Amirthalingham, Cody J. Peer, Yuanbin Chen, Richard Piekarz, Seth M. Steinberg, Jane B. Trepel, William D. Figg, David S. Schrump, Giuseppe Giaccone	2014	79
12	Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers Clinical Cancer Research ·Laleh Amiri‐Kordestani, Victoria Luchenko, Cody J. Peer, Kambiz Ghafourian, James C. Reynolds, Yosy Meliyana Batubara, Robin Frye, Guillaume Futhazar, David Venzon, John J. Wright, Monica C. Skarulis, William D. Figg, Tito Fojo, Susan E. Bates, Richard Piekarz	2013	57
13	Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel Clinical Cancer Research ·Anne M. Noonan, AHAHA雅文太田, David J. Liewehr, Tristan M. Sissung, David Venzon, Thomas P. Flagg, Mark C. Haigney, Seth M. Steinberg, William D. Figg, Richard Piekarz, Susan E. Bates	2013	39
14	A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors Clinical Cancer Research ·Arun Rajan, Corey A. Carter, Ronan J. Kelly, Martin Gutierrez, Shivaani Kummar, Éva Szabó, Mary Ann Yancey, Jiuping Ji, Baskar Mannargudi, Sukyung Woo, Shawn D. Spencer, William D. Figg, Giuseppe Giaccone	2012	125
15	A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas Clinical Cancer Research ·Arun Rajan, Ronan J. Kelly, Jane B. Trepel, Yeong Sang Kim, Sylvia V. Alarcon, Shivaani Kummar, Martin Gutierrez, Sonja Crandon, Wadih M. Zein, Lokesh Jain, Baskar Mannargudi, William D. Figg, Brett E. Houk, Michael Shnaidman, Nicoletta Brega, Giuseppe Giaccone	2011	107
16	Impact of ABCB1 Allelic Variants on QTc Interval Prolongation Clinical Cancer Research ·Tristan M. Sissung, Erin R. Gardner, Richard Piekarz, Reuben Howden, Xiaohong Chen, Sukyung Woo, Ryan M. Franke, James Clark, Laura Miller‐DeGraff, Seth M. Steinberg, David Venzon, David J. Liewehr, Steven R. Kleeberger, Susan E. Bates, Douglas K. Price, Douglas R. Rosing, Christopher H. Cabell, Alex Sparreboom, William D. Figg	2010	24
17	A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer Clinical Cancer Research ·Ronan J. Kelly, Deborah Draper, Clara C. Chen, Robert W. Robey, William D. Figg, Richard Piekarz, Xiaohong Chen, Erin R. Gardner, Frank M. Balis, Aradhana M. Venkatesan, Seth M. Steinberg, Tito Fojo, Susan E. Bates	2010	151
18	Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation Proceedings of the National Academy of Sciences ·Jinhao Lu, Lynda Erskine, Erin R. Gardner, William D. Figg, Neil Vargesson	2009	181
19	Effect of SLCO1B3 Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic Cancer Clinical Cancer Research ·Akinobu Hamada, Tristan M. Sissung, Douglas K. Price, Romano Danesi, Cindy H. Chau, Nima Sharifi, David Venzon, Kenji Maeda, Keisuke Nagao, Alex Sparreboom, Hiroaki Mitsuya, William L. Dahut, William D. Figg	2008	153
20	A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer Clinical Cancer Research ·William L. Dahut, Charity D. Scripture, Edwin M. Posadas, Lokesh Jain, James L. Gulley, Philip M. Arlen, James R. Wright, Yunkai Yu, Liang Cao, Seth M. Steinberg, Jeanny B. Aragon‐Ching, Jürgen Venitz, Elizabeth C. Jones, Clara C. Chen, William D. Figg	2008	142

About William D. Figg

William D. Figg is a scholar working on Oncology, Hematology, Pulmonary and Respiratory Medicine, Pharmacology and Cancer Research, having authored 604 papers that have together received 25.3k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (139 papers), Cancer Treatment and Pharmacology (91 papers), Multiple Myeloma Research and Treatments (83 papers), Drug Transport and Resistance Mechanisms (53 papers), Protein Degradation and Inhibitors (47 papers), Pharmacogenetics and Drug Metabolism (42 papers), Cancer therapeutics and mechanisms (41 papers) and Prostate Cancer Diagnosis and Treatment (38 papers). The work is most often cited by research in Oncology (10.0k citations), Cancer Research (3.4k citations), Hematology (2.3k citations), Molecular Biology (11.5k citations) and Pharmacology (1.3k citations). William D. Figg has collaborated with scholars based in United States, United Kingdom and Netherlands. Frequent co-authors include Alex Sparreboom, Seth M. Steinberg, Cindy H. Chau, Charity D. Scripture, William L. Dahut, Cody J. Peer, Tristan M. Sissung, Douglas K. Price, Kristina M. Cook and Erin R. Gardner. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Cancer Biology & Therapy, Blood and Cancer Chemotherapy and Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact